Paul S. Aisen
Affiliations: | Georgetown University Medical Center, Washington, DC, United States |
Area:
Neuroscience Biology, Cognitive Psychology, Psychobiology PsychologyGoogle:
"Paul Aisen"Mean distance: 53433
Children
Sign in to add trainee| Ivy V. Estabrooke | grad student | 2005 | Georgetown University Medical Center |
| Michael S. Rafii | research scientist | 2007-2007 | |
| Robert A Rissman | research scientist | 2008-2008 |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Rentz DM, Aisen PS, Atri A, et al. (2024) Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Nho K, Risacher SL, Apostolova LG, et al. (2024) CYP1B1-RMDN2 Alzheimer's disease endophenotype locus identified for cerebral tau PET. Nature Communications. 15: 8251 |
| Miller MJ, Diaz A, Conti C, et al. (2024) The ADNI4 Digital Study: A novel approach to recruitment, screening, and assessment of participants for AD clinical research. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Aisen PS, Donohue MC, Raman R, et al. (2024) The Alzheimer's Disease Neuroimaging Initiative Clinical Core. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Molina-Henry DP, Raman R, Liu A, et al. (2024) Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Grill JD, Raman R, Ernstrom K, et al. (2024) Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial. Neurology. Clinical Practice. 14: e200265 |
| Rissman RA, Langford O, Raman R, et al. (2023) Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Touroutoglou A, Katsumi Y, Brickhouse M, et al. (2023) The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Grill JD, Flournoy C, Dhadda S, et al. (2023) Eligibility rates among racially and ethnically diverse US participants in Phase 2 and Phase 3 placebo-controlled, double-blind, randomized trials of lecanemab and elenbecestat in early Alzheimer's disease. Annals of Neurology |
| Nudelman KNH, Jackson T, Rumbaugh M, et al. (2023) Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |